An interventional study of Neostigmine and Sugammadex in Neuromuscular Block, Residual, sponsored by Seoul National University Bundang Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-09.
Sponsored by Seoul National University Bundang Hospital · Not applicable, Interventional, and Supportive care
Among 14 studies testing sugammadex in Delayed Emergence from Anesthesia — 2 open to participants now, 2 under way, none of them phase 3. Sugammadex · Delayed Emergence from Anesthesia.
Among the 14 studies testing sugammadex in Delayed Emergence from Anesthesia, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 6 with no phase, and was the 3rd registered.
98 studies on the registry are indexed under Delayed Emergence from Anesthesia; 17 are open to participants now.
Browse Delayed Emergence from Anesthesia studies →2 of the 14 studies testing sugammadex in Delayed Emergence from Anesthesia are open now, in 2 countries. Recruiting first, the newest first:
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
University Hospital, Caen · Sites in France
By country, each count listing its studies:
Sugammadex: first FDA approval 2015 (BRIDION), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 8 Delayed Emergence from Anesthesia studies recruiting now, 2 (25%) set no upper age limit and 4 (50%) stop at 75 or younger; 0 take children under 18; 1 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 83 across 58 interventional studies indexed under Delayed Emergence from Anesthesia.
Median enrollment 92 across the 14 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
Seoul National University Bundang Hospital is the lead sponsor of 376 studies on the registry; 56 are open to participants now.
Seoul National University Bundang Hospital has 1 study filed under Delayed Emergence from Anesthesia — fewer than ten, so there is no comparison to draw.
1 of the studies testing sugammadex in Delayed Emergence from Anesthesia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477132University Hospital, CaenA Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old | 2027-08-01 |
Among the 14 studies testing sugammadex in Delayed Emergence from Anesthesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Compare the reversal effect of neostigmine and sugammadex using quantitative neuromuscular monitoring
At the end of surgery, decide the dosage of reversal referring to quantitative neuromuscular monitoring value (TOF). After the administration of reversal, the anesthesiologist who are going to manage the participant should not check the quantitative neuromuscular monitoring and determine the timing of extubation only with his (or her) judgement. After entering post-anaesthesia care unit (PACU) measure the TOF value and check the incidence of TOF ratio > 0.9 between the neostigmine group and sugammadex group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At the end of surgery, administrating neostigmine to participants according to the protocol below: when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg
Drug: Neostigmine
At the end of surgery, administrating sugammadex to participants according to the protocol below: when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg
Drug: Sugammadex
Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal
Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
Also known as: Bridion
the incidence of postoperative residual curarization
definition of postoperative residual curarization: TOF ration is 0.9 or over 0.9
Time frame: Immediately after entering PACU
Plan to share: Undecided
Ran from Sep 2017 to primary completion in Nov 2017, 2 months.
Of 20 interventional studies with no phase under Delayed Emergence from Anesthesia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Neostigmine · Sugammadex
Delayed Emergence from Anesthesia →
Seoul National University Bundang Hospital →